Sign in
CompletedNo phase

Melatonin for Knee Osteoarthritis Patients

Key facts

Who runs it
Xiangya Hospital of Central South University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
340 people enrolled
Started
2 Nov 2023
Ended
24 Sept 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Melatonin
  • Placebo
Record updated
20 November 2025

Who can take part

Age
40 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Age between 40 and 80 years
  • Knee OA according to the American College of Rheumatology (ACR) clinical criteria
  • Knee pain lasting 3 months or longer and a score of 7 or greater on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale (standardized to range from 0-20)
  • Kellgren-Lawrence (KL) grade 2 or 3
  • Willing and able to provide written informed consent

Who cannot take part

  • Any use of anti-depressive/psychotropic drugs
  • History of injections of corticosteroids in the past three months or hyaluronic acid in the past 6 months in the index knee
  • History of arthroscopy or open surgery in the index knee in the past 12 months
  • History of a knee replacement in the index knee or planning to receive such a procedure within 3 months
  • History of a severe injury in the index knee
  • Pain in the index knee caused by inflammatory, autoimmune, neoplastic diseases or other diseases
  • Severe cardiopulmonary diseases
  • Uncontrolled hypertension or diabetes mellitus
  • Diagnosis of malignant tumors
  • Allergic to melatonin or its preparation
  • Abnormal liver or kidney functions, as defined by alanine transaminase or aspartate aminotransferase >two times the upper limit of normal, or blood urea nitrogen or serum creatinine >two times the upper limit of normal
  • Any use of NSAIDs or other analgesics in the past two weeks
  • Pregnant or contemplating pregnancy or breastfeeding
  • Any use of melatonin supplement before enrollment within 30 days

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

By recruiting knee osteoarthritis patients and treating them with melatonin, this study aims to determine the efficacy and safety of melatonin in alleviating pain in this patient population.

The 2 groups in the trial

  • Oral melatonin supplementationTreatment being tested

    Participants in the intervention arm will receive one 3 mg melatonin tablet every night before going to bed

    Treatment: Melatonin

  • PlaceboPlacebo, for comparison

    The control group will receive an identical-looking inert placebo tablet every night before going to bed

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Melatonin for Pain Relief in Knee Osteoarthritis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial
Record updated
20 November 2025